Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes.
about
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agentsMacrocyclic histone deacetylase inhibitorsEpimutational profile of hematologic malignancies as attractive target for new epigenetic therapiesTrials with 'epigenetic' drugs: an updatePanobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cellsPanobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51Histone Deacetylase Inhibitor Romidepsin Has Differential Activity in Core Binding Factor Acute Myeloid LeukemiaClinical Toxicities of Histone Deacetylase Inhibitors.Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors.Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS).Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia.Epigenetic therapies for chemoresensitization of epithelial ovarian cancer.Leukaemogenesis: more than mutant genesHistone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors.Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer.A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03.Interpreting clinical assays for histone deacetylase inhibitors.Targeting inflammation in heart failure with histone deacetylase inhibitors.Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphomaEpigenomics and ovarian carcinoma.Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects.A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia.Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agentsChromatin, cancer and drug therapies.Targeting histone deacetylases for the treatment of diseaseNew clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer.Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells.Personalized therapies in the cancer "omics" eraEmerging role of the histone deacetylase inhibitor romidepsin in hematologic malignancies.The role of HDACs inhibitors in childhood and adolescence acute leukemias.Epigenetic regulation in myelodysplastic syndromes: implications for therapy.HDACi: cellular effects, opportunities for restorative dentistry.Histone methylation in myelodysplastic syndromes.Promises and challenges of anticancer drugs that target the epigenome.Multiple roles of class I HDACs in proliferation, differentiation, and development.Epigenetics and blood disorders.HDAC inhibitor-based therapies: can we interpret the code?Toxicological and metabolic considerations for histone deacetylase inhibitors.Chromatin modifications remodel cardiac gene expression.Deacetylase inhibitors for the treatment of myelodysplastic syndromes.
P2860
Q21198868-114213D5-1454-478F-8A8E-5447619407AEQ24629065-161BE811-E03D-4388-AED0-E09E9591F6DEQ26744080-D6696781-E5C6-462F-9FC9-D3D1A134DB09Q27000542-BBBC01F6-781D-4383-9FB1-BB05549AAE85Q28533896-A6B5408F-5A7B-4012-8D99-D8E475B6B32EQ28535006-50CC6C45-79A1-49FF-B939-8CDC29B58352Q29394054-B25945A5-1129-4421-8604-F6671D6447C8Q31135325-29115847-D7B1-41CD-9743-93E6A9D39C5FQ33390876-72962EAA-683F-4C28-BEBA-D4C16ECB96C3Q33395173-D9602430-D341-4A9E-BED2-67D0755B7001Q33437309-2ACC317A-3A29-4295-9A43-6D21DA4E31D8Q33621141-D5D3FAEF-0FB6-42D6-9220-2E28FEAF0F1AQ34275371-09A01D2E-3CEF-4BE1-AECC-EC85E7346F78Q34416994-33E66C75-1F7D-4F56-AD58-E255A7A86B53Q34808616-B7154705-71D7-47E8-80F2-2E781EE02E9CQ34977381-C6E47680-FFFD-4D4D-9E27-BDDBFE128F5EQ35003657-F616E02D-AC2C-4EE3-9977-F717046EE529Q35016989-168324E2-CCC5-436F-AEBF-1D599170B5CCQ35186682-11569599-582E-42E9-B57A-C64C36F211F2Q35636575-09003E48-34BE-4534-B543-2D13FC49F454Q35939690-05A2EA8A-237B-4E09-B454-5AB7A2DCCBFFQ36395421-E7783E5D-1572-491F-90C4-3EA698A3CCC7Q36645808-496ACF38-87D6-4FB0-9621-DD3E4F1A7357Q37073231-75F8DC8D-0BC2-4958-B023-57D6E8C77AB5Q37296159-92B1243B-BCB9-472A-A301-0C0E7B2CD1D7Q37503780-B85E2A5F-9BF3-4581-B70C-AFA543E69E86Q37621254-81821C80-D1E2-43F8-9F08-0505E70A914BQ37776547-9C4436F5-D202-4E96-AA7A-916BCD646D8AQ37809875-5D4EE014-2274-4635-96FF-254CDA82DD3EQ37841146-A7AC8907-9AD0-4028-A667-9DF20280FCC1Q37850456-7F141C84-433E-4533-9654-A6EE5C398B97Q37871246-A5C6B734-49C6-4FC1-BE0B-AACB77935545Q37961859-0899664F-61F2-412C-9CF4-4373C370B193Q37962596-97E054E4-2F9F-40FB-A0C6-3F6F357AED05Q37979639-0273E46B-F54A-482D-94B3-90DF5F822ED3Q38019955-387D0FF4-7B0B-420C-810A-61513BCA2CA5Q38058971-56FD6DA9-8EBC-4CFC-9F5B-45CB6EBE9684Q38071321-7C2FAD93-7E0D-40AF-B751-D2E8704339A4Q38210525-D703A6FE-48BB-4C13-9474-B6D6730A8CB0Q38233492-268895E9-7D2F-45DD-8CC3-3CE3013E7229
P2860
Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes.
description
2008 nî lūn-bûn
@nan
2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
name
Tolerability, pharmacodynamics ...... ced myelodysplastic syndromes.
@ast
Tolerability, pharmacodynamics ...... ced myelodysplastic syndromes.
@en
type
label
Tolerability, pharmacodynamics ...... ced myelodysplastic syndromes.
@ast
Tolerability, pharmacodynamics ...... ced myelodysplastic syndromes.
@en
prefLabel
Tolerability, pharmacodynamics ...... ced myelodysplastic syndromes.
@ast
Tolerability, pharmacodynamics ...... ced myelodysplastic syndromes.
@en
P2093
P1476
Tolerability, pharmacodynamics ...... ced myelodysplastic syndromes.
@en
P2093
Ilhem Guernah
John J Wright
Katherine Panageas
Michael Baum
Sophia Fircanis
Stephen D Nimer
Virginia M Klimek
P304
P356
10.1158/1078-0432.CCR-07-0318
P407
P577
2008-02-01T00:00:00Z